(NASDAQ: MORF) Morphic Holding's forecast annual revenue growth rate of 441.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Morphic Holding's revenue in 2024 is $521,000.On average, 1 Wall Street analysts forecast MORF's revenue for 2028 to be $4,888,637,273, with the lowest MORF revenue forecast at $4,888,637,273, and the highest MORF revenue forecast at $4,888,637,273. On average, 1 Wall Street analysts forecast MORF's revenue for 2029 to be $19,244,318,273, with the lowest MORF revenue forecast at $19,244,318,273, and the highest MORF revenue forecast at $19,244,318,273.
In 2030, MORF is forecast to generate $60,800,236,958 in revenue, with the lowest revenue forecast at $60,800,236,958 and the highest revenue forecast at $60,800,236,958.